Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for AGGRENOX
- Aggrenox To Treat Acute Covid-19
- Oxidative Stress and Oxysterols Profiling in Patients With Carotid Revascularization
- Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers
- Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers
- Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects
- Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH
- Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers
- Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
- Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers
- GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
- EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
- JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
- Headache Study to Compare Aggrenox Full Dose and Reduced Dose
- Treatment of Supine Hypertension in Autonomic Failure
- PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
- Aggrenox Prevention of Access Stenosis
Clinical trials list
click for details